SUMMARY The electrophysiologic effects of n-acetylprocainamide (NAPA) and procainamide (PA) were compared in 14 chloralose-anesthetized dogs using intracardiac electrography and programmed stimulation. With five successive sequences of an intravenous bolus followed by a 45-minute infusion, plasma concentrations (Cp) ranged from 1.8 ± 0.1 to 32 ± 2 g/ml for PA and from 8.2 ± 0.3 to 125 i 7 ,ug/ml for NAPA. In 6, 1979. between the electrophysiologic effects and plasma drug concentration (Cp).
producing parallel Cp-dependent increases of QTc and WCL. Atrial RPs were prolonged by both drugs with parallel Cp response curves and PA was slightly more potent than NAPA. The PA Cp-dependent increase of nodal functional RP was greater than the effects of NAPA and the Cp-response curves were not parallel. Both drugs increased ventricular RP. The maximum effect of PA always occurred at the highest drug concentration, while the peak effect of NAPA on some measured parameters occurred during the postinfusion decay period. We conclude that in addition to differences in pharmacokinetics NAPA and PA may have different mechanisms of action, different effective antiarrhythmic concentrations and different electrical cardiac toxicities.
PROCAINAMIDE pharmacokinetic studies in man show that n-acetylprocainamide (NAPA) is the major metabolite of procainamide.1-8 Studies in animal arrhythmia models4' 9-" and in man4 12 indicate that NAPA exerts antiarrhythmic effects that may be partly responsible for the antiarrhythmic effect of procainamide.6 Initial studies suggest that NAPA may not have the same propensity to induce systemic lupus as procainamide.9 If these observations are correct, NAPA might become an alternative antiarrhythmic drug.
To investigate the mechanism of the antiarrhythmic action of NAPA, several electrophysiologic studies in isolated tissue preparations", 13 have shown that some effects of NAPA and procainamide were different. In the dog heart in situ, Amlie et al.14 found that NAPA did not increase His-Purkinje and atrioventricular (AV) nodal conduction times and was less potent than procainamide in increasing the AV nodal functional refractory period. However, they used only two drug doses and did not find a significant correlation between the electrophysiologic effects and plasma drug concentration (Cp) .
In the present study we compared the electrophysiologic properties of NAPA and procainamide in closed-chest, anesthetized dogs using His bundle electrography and programmed electrical stimulation. The effects of the drugs were examined over a wide range of Cps achieved by different intravenous infusion rates.
Methods

General Procedures
Seventeen mongrel dogs of either sex (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) kg, average 24 kg) were anesthetized with morphine sulfate 2 mg/kg subcutaneously, followed 30 minutes later by a-chloralose 200 mg/kg intravenously (4% solution in polyethylene glycol and distilled water). The dogs were intubated with a cuffed endotracheal tube. Artificial ventilation was maintained with a Harvard respirator pump using humidified room air. A large polyethylene catheter was inserted into the left femoral artery to monitor the systemic arterial pressure using a Statham P23Db transducer. The mean arterial blood pressure was calculated using the formula BP = diastolic pressure + 1/3 of the pulse pressure.'5 The same catheter was used to draw blood samples for arterial blood gas analysis using a Corning model 165 blood gas analyzer. Depth and rate of respiration were adjusted to maintain an arterial Po2 over 72 mm Hg and pH between 7.35 and 7.44 throughout the experiment.
A catheter was placed in the left femoral vein for administration of additional anesthetic, which was given hourly (10 ml of 4% chloralose solution) to VOL 60, No 6, DECEMBER 1979 maintain deep anesthesia. The left jugular vein was catheterized for drug infusion. Surface leads II and III of the ECG were continuously monitored.
Electrophysiologic Studies
Sinus cycle length (SCL), intraventricular conduction times (QRS) and QT interval (corrected QT, according to the Bazett formula'6) were measured at the spontaneous sinus rate using the external ECG and a recording speed of 100 mm/sec.
A USCI #7F tripolar electrode catheter was positioned via the right carotid artery in the root of the aorta at the level of the aortic cusps to record His bundle electrograms.17 This signal was preamplified and filtered (20 and 200 Hz) and displayed on a 7623A Tektronix oscilloscope at a speed of 1000 mm/sec. A picture of the HV interval was then taken using a Polaroid C-5 oscilloscope camera. His bundle-toventricular activation time (HV) was measured from the beginning of the bundle of His electrogram to the earliest ventricular depolarization recorded on the intracardiac electrogram. This arrangement allows measurement of HV interval to within ± 1.0 msec. Care was taken throughout the experiment to be certain that the onset of this intracardiac ventricular electrogram maintained a constant relationship to the earliest ventricular activation in any surface or intracardiac lead. AH was the interval from the beginning of the atrial depolarization (A) to the beginning of the bundle of His bipolar electrogram (H) measured at 100 mm/sec.
Two additional USCI electrode catheters were positioned, one tripolar into the right ventricle via the right femoral vein and one quadripolar in the right atrium via the right jugular vein. The two distal electrodes of the right atrial and the right ventricular catheters were connected to a model 850A stimulus isolation unit of a programmable stimulator (W.P. Instruments, preset control 842, interval generator 830, pulse modules 831A). The signal from the two proximal electrodes of the right atrial catheter was preamplified, filtered and recorded in order to permit accurate recognition of the atrial depolarization during the studies of AV nodal refractory periods.
The functional and effective refractory periods of the right ventricle (VFRP and VERP, respectively) were determined when the ventricle was paced at a fixed cycle length (300 msec) using a 2-msec duration rectangular pulse S, and a twice-diastolic-threshold intensity (mean diastolic ventricular threshold = 0.8 mA ± 0.16 [SEM] ). A premature ventricular stimulus S, of same duration and intensity as S, was delivered after every eight regularly delivered S, stimuli at progressively shorter intervals (20-msec steps from 260 to 200 msec, then 10-msec steps) until S2 failed to depolarize the ventricle. Each S2 was followed by a 1200-msec pause of stimulation in order not to interfere with the cardiac spontaneous response to S2. The VFRP was defined as the shortest attainable V,V2
interval, and the VERP as the longest S1S2 interval To study the automaticity of the sinoatrial node, the post-overdrive pacing pause of sinus node recovery time (SNRT) was measured according to Mandel et al.20 All the recordings were done on an eight-channel Honeywell 1508 visicorder at a paper speed of 100 mm/sec.
Protocols
The effects of NAPA were studied in eight dogs and the effects of procainamide in six dogs. The doses of NAPA and procainamide ( procainamide solution and no procainamide present in the NAPA solution.
Procainamide and NAPA Concentration Determinations Five milliliters of blood were drawn for each determination. The plasma was immediately separated by centrifugation and frozen until analysis. Cp of both drugs were determined by a specific, high-performance liquid chromatography assay22 modified with ion-paired chromatography. Drugs were extracted from plasma into ethyl-acetate after buffering with sodium bicarbonate pH 10. The lower limit of sensitivity of the assay was 0.1 ,ug/ml for NAPA and procainamide.
Data Analysis
All data are presented as mean ± SEM. For each dog, the blood pressure and electrophysiologic data measured during and after the five infusions of NAPA or procainamide were expressed as percentage of change compared to the basal values. The two-tailed t test was used to compare the basal values in the two groups of dogs (unpaired data). Log-linear regression analyses were performed in each dog to determine the relationship between the logarithm of the plasma concentration of NAPA or procainamide and individual electrophysiologic effects expressed in terms of percent change. Mean slopes of the regression lines were obtained in each group and the one-tailed t test was used to test the difference of mean slopes from 0 and the independent group t test to compare mean slopes between the two groups. The level of significance was p < 0.05.
For each dog of the control group, the coefficient of variation (CV) of each parameter was calculated by dividing the standard deviation by the mean of the absolute values of the parameter recorded during the experiment. Then CVs of the three dogs were averaged, expressed in percentage and presented as mean ± SEM CV%.
Results
Control Dogs
Three control dogs were studied to assess the stability of the electrophysiologic measurements during a prolonged (320, 340 and 405 minutes) chloralose anesthesia. mean of Cp at 30 minutes and 45 minutes was calculated for each infusion in each dog and was used to establish all the concentration-response curves. After the end of the fifth infusion, Cps of NAPA and procainamide decreased progressively ( fig. 1 ) with time, but the blood sampling period of time was not long enough to allow accurate comparison of the disposition of the drugs. In the six dogs that received procainamide no measurable acetylation of procainamide was observed during the study. In the eight dogs that received NAPA, a low Cp of procainamide (0.2-0.3 ug/ml) appeared after the first infusion of NAPA and did not increase. This deacetylation process probably occurred during the extraction of the drug from the plasma, because previous experiences in our laboratory have shown that extraction of NAPA from a normal saline solution resulted in a similar level of procainamide.
Electrophysiologic Results
The electrophysiologic data are summarized in table 3. Sinoatrial Node A utomaticity
The basal values of SCL and SNRT in both groups of dogs were not significantly different. Both NAPA and procainamide showed decreases in SCL and SNRT during the first infusion and progressive increases during subsequent infusions. However, none of the mean slopes of the concentration-response curves of these parameters were significantly different from 0.
Conduction Times
The basal AH, HV and QRS intervals were not significantly different between the NAPA and the procainamide groups.
NAPA did not significantly alter AH interval at any Cp. Procainamide initially decreased the AH interval during infusions 1 and 2 then it increased, resulting in a concentration-dependent increase with a mean slope significantly different from 0 (p < 0.01) and from the mean slope of the NAPA group (p < 0.01).
HV conduction time increased progressively during NAPA infusions. The overall change was small, however, and reached a maximum of + 12.9 ± 3.3% during the fifth infusion at a Cp of 125 ug/ml. The mean slope of the concentration-dependent increase was significantly different from 0 (p < 0.01) ( fig. 2) . During procainamide infusions, HV increased progressively to a maximum of + 44.3 ± 4.9% during the fifth infusion. The mean slope of the concentration-dependent increase was significantly different from 0 (p < 0.01). The mean slopes of the concentration-response curves of NAPA and procainamide were significantly different (p < 0.01) and procainamide exerted a much more potent effect than NAPA on the conduction in the His-Purkinje system. Two hours after the end of the fifth infusion, HV remained significantly longer than basal for both NAPA (+10.9 ± 2.8%) and procainamide (+31 ± 7%) at a time when Cps were 62.7 ± 2.5 Atg/ml and 13.5 ± 0.7 jug/ml, respectively.
The QRS interval increased slightly during the fifth infusion of NAPA but the mean slope of the concentration-response curve was not significantly different from 0 ( fig. 3) . During the third, fourth, and fifth infusions of procainamide, QRS interval increased and the mean slope of the concentrationresponse curve was significantly different from 0 (p < 0.01) and from the slope of the NAPA group The Wenckebach Phenomenon Cycle Length
The basal values of WCL were not significantly different between the NAPA and procainamide groups. Both drugs produced an equivalent concentration-dependent increase in WCL (p < 0.01 for NAPA and p < 0.01 for procainamide) and the potency and slopes of their concentration-response curves were not significantly different ( fig. 8) . However, after the end of the last infusion of NAPA, WCL continued to increase to a maximum of 35 ± 7.5% at 120 minutes. In the procainamide group WCL decreased after the fifth infusion.
Blood Pressure
Basal values of blood pressure were not significantly different between the groups. Neither NAPA nor procainamide caused a statistically significant change in blood pressure measured at 30 minutes of each of the five infusions.
Discussion
Procainamide has been used for many years to treat arrhythmias. However, the high incidence of immunologic reactions23' 24 limits the long-term use of procainamide as an antiarrhythmic agent. NAPA, the principal metabolite of procainamide in man,9 may not have this toxicity and may become an alternative drug inasmuch as it has antiarrhythmic activity in both animal models4 9, 10 and in patients. 4 Our study in chloralose-anesthetized dogs showed no significant effect on either heart rate or SNRT. Although the changes did not reach statistical significance, both drugs slightly increased heart rate and shortened SNRT at lower concentrations and slowed heart rate and prolonged SNRT at higher concentrations. This trend was most marked for procainamide. The conflicting data in published studies may result from a dual action of these compounds. One might postulate that net effect of the drugs on the sinus node may be the result of predominant vagolytic action32 at lower drug concentrations and overriding direct depressant actions of higher concentrations.
Conduction Times
Although the effects of procainamide and NAPA on the intracardiac conduction times depend on the portion of the conduction pathway measured, overall, procainamide seems to exert a much more potent effect than NAPA.
1) NAPA did not increase significantly the atrionodal conduction time always measured at the same driven atrial rate, while procainamide produced a concentration-dependent increase. The lack of effect of NAPA on AH conduction time is consistent with the findings of Amlie et al. '4 The data are conflicting with regard to the effect of procainamide both in dogs or in humans; some authors finding a negative dromotropic effect,4' 33 some a positive dromotropic effect26 and others no significant effect.29-3" Once again, mixed vagolytic and direct effects could explain these discrepancies.
2) In our study procainamide prolonged the HisPurkinje and the intraventricular conduction times in a log-linear relationship with Cp. These data are consistent with the data in anesthetized dogs,14 25 33 in conscious dogs24 and in patients.29-3" This is also consistent with the effects of procainamide on the electrophysiologic properties of isolated canine Purkinje fibers: a decrease of conduction velocity and of the amplitude and the maximal rate of rise of phase 0 of the action potential. '7 The effects of NAPA on HV conduction times were different from those of procainamide. NAPA produced a significant concentration-dependent increase of HV, but compared with the effects of procainamide, the latter exerted a much more important effect. The maximum NAPA-induced increase in HV occurred during the fifth infusion, when the Cp was around 125 ,tg/ml. Amlie et al. ' 4 investigated the effects of NAPA only to a maximum Cp of 30 ,ug/ml and did not find any significant change of HV. Our data are consistent with these results because at this lower Cp, the increase of HV in our experiment was small and not significant. The effect of NAPA on the intraventricular conduction time was also much different from that of procainamide. This minimal effect of NAPA on QRS duration and its very weak negative dromotropic effect on His-Purkinje conduction make NAPA different from procainamide. These results are in agreement with the recent findings of Dangman and Hoffman,'34 who showed that in canine cardiac Purkinje fibers, NAPA exerted no significant change of the maximal velocity of the upstroke (phase 0) of the action potential at concentrations of 20 and 40 ,g/ml.
Cardiac Refractory Periods and QT, Interval Both procainamide and NAPA increased the AERP and AFRP in relation to the log of the Cp. These results confirmed the data of Amlie et al.'4 in anesthetized dogs and those of Minchin et al." on isolated rabbit atria and those of Refsum et al." on isolated rat atria. Our results are similar to these later studies in that we found NAPA was slightly less effective than procainamide in increasing atrial refractory periods. Procainamide had previously been shown to' increase the duration of atrial refractory periods both in anesthetized dogs33 and in patients.29 ' 31 The AV nodal refractory periods were increased both by procainamide and NAPA and both drugs were equipotent for increasing the Wenckebach cycle length. The effects on the NFRP are in agreement with those of Amlie et al.,14 but the studies of Josephson et al."I and Ogunkelu et al. '9 showing no significant effect of procainamide on NFRP and a decrease of NERP are in conflict with our results. However, these two studies were done in patients, where the neural control of the AV nodal conduction time may be different from that in anesthetized dogs.
Both procainamide and NAPA increased VFRP, VERP, and QT,. 11 ,gg/ml of NAPA is required to suppress ventricular premature complexes.
In conclusion, NAPA may have different electrophysiologic properties from its parent compound, procainamide.At a clinically relevant Cp NAPA has almost no effect on His-Purkinje and intraventricular conduction times and a less important effect on the atrial and AV nodal refractory periods. These data suggest that in addition to their differences in pharmacokinetics, the drugs may have different antiarrhythmic mechanisms of action, different effective antiarrhythmic concentrations and different electrical cardiac toxicities.
